Welcome to our dedicated page for SI-BONE news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on SI-BONE stock.
SI-BONE, Inc. reports developments for a medical device business focused on procedural solutions for compromised bone and sacropelvic disorders. The company develops technologies centered on spinopelvic anatomy, including applications in minimally invasive SI joint fusion, adult spinal deformity, spinopelvic and sacropelvic fixation, and pelvic trauma.
Recurring updates include quarterly and annual financial results, revenue guidance, cash flow and adjusted EBITDA commentary, physician adoption metrics, reimbursement developments, and healthcare conference presentations. Product references include the iFuse Implant System, iFuse Bedrock Granite, iFuse TORQ, iFuse TORQ TNT, iFuse 3D, and related surgical implant technologies.
SI-BONE, Inc. (Nasdaq: SIBN), a medical device company, will participate in the Bank of America Securities 2020 Health Care Conference on May 13, 2020. The management team will conduct a live Fireside Chat at 8:40 a.m. PT / 11:40 a.m. ET, accessible via the company's website. SI-BONE specializes in minimally invasive surgery for sacroiliac joint disorders with its iFuse Implant System, which has shown significant clinical benefits in treating chronic low back pain. The company emphasizes the importance of their research-backed device in enhancing patient outcomes.
SI-BONE, Inc. (Nasdaq:SIBN) reported Q1 2020 revenue of $16.8 million, marking a 12% increase year-over-year. U.S. revenue reached $15.3 million, a 14% rise, despite lower case volumes in late March due to COVID-19. Gross margin stood at 89%, down from 90% in 2019, while operating expenses rose 20% to $26.8 million. The net loss was $12.8 million, or $0.47 per diluted share, compared to $9.3 million in the same period last year. The company has withdrawn its 2020 guidance due to COVID-19 uncertainties.